The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02126592

Enrollment

100

Registered

2014-04-30

Start date

2013-03-31

Completion date

2014-05-31

Last updated

2014-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Brief summary

Polycystic ovary syndrome (PCOS) is an endocrine disease in reproductive women. It is characterized by anovulation and hyperandrogenism. Most patients with PCOS have metabolic abnormalities such as dyslipidemia, insulin resistance and glucose abnormalities. Almost 60-80﹪PCOS patients are obesity which exacerbates IR and hyperandrogenism. Obese PCOS patients tend to be overeating suggests that impaired appetite regulation might be contribute to the pathophysiology of PCOS. Our study is trying to observe difference of incretin between PCOS and normal control to figure out whether change of incretin is involved in the pathophysiology of PCOS.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

13 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* women at reproductive age * women with PCOS and women without PCOS

Exclusion criteria

* young women who had their menarche less than 3 years * women older than 45 years old, Amenorrhea of menopause, hyperglycemia, hyperthyroidism, hypothyroidism, heart failure, lung failure, renal failure, anemia, dystrophy, gonitis

Design outcomes

Primary

Measure	Time frame
Change in incretin hormones secretion in PCOS patients.	up to 14 months

Countries

China

Contacts

Primary ContactJing Ma, Dr.

cherry1996@live.cn+86-21-68383083

Outcome results